nodes	percent_of_prediction	percent_of_DWPC	metapath
Methotrexate—esophageal cancer—pharynx cancer	0.401	0.425	CtDrD
Methotrexate—bone cancer—pharynx cancer	0.288	0.305	CtDrD
Methotrexate—muscle cancer—pharynx cancer	0.254	0.27	CtDrD
Methotrexate—SLC19A1—tongue—pharynx cancer	0.00332	0.0588	CbGeAlD
Methotrexate—FOLR1—mouth—pharynx cancer	0.00254	0.0451	CbGeAlD
Methotrexate—SLC19A1—mouth—pharynx cancer	0.00223	0.0396	CbGeAlD
Methotrexate—FOLR1—parotid gland—pharynx cancer	0.00177	0.0314	CbGeAlD
Methotrexate—FOLR1—saliva-secreting gland—pharynx cancer	0.0017	0.0301	CbGeAlD
Methotrexate—FOLR1—epithelium—pharynx cancer	0.00148	0.0262	CbGeAlD
Methotrexate—FOLR1—trachea—pharynx cancer	0.00131	0.0232	CbGeAlD
Methotrexate—GGH—parotid gland—pharynx cancer	0.00118	0.0209	CbGeAlD
Methotrexate—FOLR1—lymphoid tissue—pharynx cancer	0.00114	0.0202	CbGeAlD
Methotrexate—GGH—saliva-secreting gland—pharynx cancer	0.00113	0.02	CbGeAlD
Methotrexate—SLCO4C1—parotid gland—pharynx cancer	0.00104	0.0185	CbGeAlD
Methotrexate—SLC19A1—lymphoid tissue—pharynx cancer	0.001	0.0177	CbGeAlD
Methotrexate—FPGS—saliva-secreting gland—pharynx cancer	0.000991	0.0176	CbGeAlD
Methotrexate—ATIC—brainstem—pharynx cancer	0.000939	0.0167	CbGeAlD
Methotrexate—FOLR1—head—pharynx cancer	0.000918	0.0163	CbGeAlD
Methotrexate—MTHFR—neck—pharynx cancer	0.000913	0.0162	CbGeAlD
Methotrexate—GGH—trachea—pharynx cancer	0.00087	0.0154	CbGeAlD
Methotrexate—ATIC—epithelium—pharynx cancer	0.000836	0.0148	CbGeAlD
Methotrexate—SLC19A1—head—pharynx cancer	0.000805	0.0143	CbGeAlD
Methotrexate—PGD—neck—pharynx cancer	0.000793	0.0141	CbGeAlD
Methotrexate—SLCO4C1—trachea—pharynx cancer	0.000771	0.0137	CbGeAlD
Methotrexate—SLC46A1—lymphoid tissue—pharynx cancer	0.00077	0.0137	CbGeAlD
Methotrexate—FPGS—trachea—pharynx cancer	0.000765	0.0136	CbGeAlD
Methotrexate—SLC46A1—spinal cord—pharynx cancer	0.000698	0.0124	CbGeAlD
Methotrexate—GGH—spinal cord—pharynx cancer	0.000687	0.0122	CbGeAlD
Methotrexate—FPGS—lymphoid tissue—pharynx cancer	0.000666	0.0118	CbGeAlD
Methotrexate—PGD—parotid gland—pharynx cancer	0.000646	0.0115	CbGeAlD
Methotrexate—ATIC—lymphoid tissue—pharynx cancer	0.000644	0.0114	CbGeAlD
Methotrexate—DHFR—saliva-secreting gland—pharynx cancer	0.000644	0.0114	CbGeAlD
Methotrexate—SLC46A1—head—pharynx cancer	0.00062	0.011	CbGeAlD
Methotrexate—PGD—saliva-secreting gland—pharynx cancer	0.000619	0.011	CbGeAlD
Methotrexate—GGH—head—pharynx cancer	0.00061	0.0108	CbGeAlD
Methotrexate—FPGS—spinal cord—pharynx cancer	0.000604	0.0107	CbGeAlD
Methotrexate—ATIC—spinal cord—pharynx cancer	0.000584	0.0104	CbGeAlD
Methotrexate—SLC19A1—lymph node—pharynx cancer	0.000564	0.01	CbGeAlD
Methotrexate—ABCC10—parotid gland—pharynx cancer	0.000554	0.00982	CbGeAlD
Methotrexate—FPGS—head—pharynx cancer	0.000537	0.00951	CbGeAlD
Methotrexate—ABCC10—saliva-secreting gland—pharynx cancer	0.000531	0.00941	CbGeAlD
Methotrexate—ATIC—head—pharynx cancer	0.000519	0.0092	CbGeAlD
Methotrexate—SLC16A1—epithelium—pharynx cancer	0.000504	0.00894	CbGeAlD
Methotrexate—DHFR—trachea—pharynx cancer	0.000497	0.0088	CbGeAlD
Methotrexate—SLCO1C1—spinal cord—pharynx cancer	0.000485	0.00861	CbGeAlD
Methotrexate—MTHFR—lymphoid tissue—pharynx cancer	0.000479	0.00849	CbGeAlD
Methotrexate—PGD—trachea—pharynx cancer	0.000477	0.00846	CbGeAlD
Methotrexate—TYMS—lymphoid tissue—pharynx cancer	0.000437	0.00774	CbGeAlD
Methotrexate—SLC46A1—lymph node—pharynx cancer	0.000434	0.0077	CbGeAlD
Methotrexate—DHFR—lymphoid tissue—pharynx cancer	0.000432	0.00767	CbGeAlD
Methotrexate—SLCO1C1—head—pharynx cancer	0.000431	0.00765	CbGeAlD
Methotrexate—GGH—lymph node—pharynx cancer	0.000427	0.00758	CbGeAlD
Methotrexate—SLCO3A1—spinal cord—pharynx cancer	0.000427	0.00757	CbGeAlD
Methotrexate—AOX1—trachea—pharynx cancer	0.000421	0.00746	CbGeAlD
Methotrexate—PGD—lymphoid tissue—pharynx cancer	0.000416	0.00737	CbGeAlD
Methotrexate—ABCC10—trachea—pharynx cancer	0.000409	0.00726	CbGeAlD
Methotrexate—DHFR—spinal cord—pharynx cancer	0.000392	0.00695	CbGeAlD
Methotrexate—ABCC1—parotid gland—pharynx cancer	0.000392	0.00695	CbGeAlD
Methotrexate—MTHFR—head—pharynx cancer	0.000386	0.00684	CbGeAlD
Methotrexate—SLCO3A1—head—pharynx cancer	0.00038	0.00673	CbGeAlD
Methotrexate—PGD—spinal cord—pharynx cancer	0.000377	0.00668	CbGeAlD
Methotrexate—FPGS—lymph node—pharynx cancer	0.000376	0.00666	CbGeAlD
Methotrexate—ATIC—lymph node—pharynx cancer	0.000363	0.00644	CbGeAlD
Methotrexate—ABCC10—lymphoid tissue—pharynx cancer	0.000357	0.00632	CbGeAlD
Methotrexate—TYMS—head—pharynx cancer	0.000352	0.00624	CbGeAlD
Methotrexate—SLC16A1—spinal cord—pharynx cancer	0.000352	0.00624	CbGeAlD
Methotrexate—DHFR—head—pharynx cancer	0.000348	0.00618	CbGeAlD
Methotrexate—PGD—head—pharynx cancer	0.000335	0.00594	CbGeAlD
Methotrexate—ABCG2—parotid gland—pharynx cancer	0.000324	0.00575	CbGeAlD
Methotrexate—ABCC10—spinal cord—pharynx cancer	0.000323	0.00573	CbGeAlD
Methotrexate—SLC16A1—head—pharynx cancer	0.000313	0.00555	CbGeAlD
Methotrexate—ABCG2—saliva-secreting gland—pharynx cancer	0.000311	0.00551	CbGeAlD
Methotrexate—SLCO1C1—lymph node—pharynx cancer	0.000302	0.00536	CbGeAlD
Methotrexate—ABCC1—trachea—pharynx cancer	0.00029	0.00513	CbGeAlD
Methotrexate—ABCC3—head—pharynx cancer	0.000289	0.00512	CbGeAlD
Methotrexate—SLCO1A2—spinal cord—pharynx cancer	0.000279	0.00494	CbGeAlD
Methotrexate—MTHFR—lymph node—pharynx cancer	0.00027	0.00479	CbGeAlD
Methotrexate—SLCO3A1—lymph node—pharynx cancer	0.000266	0.00471	CbGeAlD
Methotrexate—SLCO1A2—head—pharynx cancer	0.000248	0.00439	CbGeAlD
Methotrexate—TYMS—lymph node—pharynx cancer	0.000246	0.00437	CbGeAlD
Methotrexate—DHFR—lymph node—pharynx cancer	0.000244	0.00433	CbGeAlD
Methotrexate—ABCC4—head—pharynx cancer	0.000238	0.00422	CbGeAlD
Methotrexate—SLC22A8—head—pharynx cancer	0.000236	0.00419	CbGeAlD
Methotrexate—PGD—lymph node—pharynx cancer	0.000235	0.00416	CbGeAlD
Methotrexate—SLC16A1—lymph node—pharynx cancer	0.000219	0.00388	CbGeAlD
Methotrexate—AOX1—lymph node—pharynx cancer	0.000207	0.00366	CbGeAlD
Methotrexate—ABCC3—lymph node—pharynx cancer	0.000202	0.00358	CbGeAlD
Methotrexate—ABCC10—lymph node—pharynx cancer	0.000201	0.00357	CbGeAlD
Methotrexate—ABCG2—spinal cord—pharynx cancer	0.000189	0.00336	CbGeAlD
Methotrexate—ALB—lymph node—pharynx cancer	0.000172	0.00306	CbGeAlD
Methotrexate—ABCC4—lymph node—pharynx cancer	0.000167	0.00296	CbGeAlD
Methotrexate—ABCC2—lymph node—pharynx cancer	0.000162	0.00286	CbGeAlD
Methotrexate—ABCC1—lymph node—pharynx cancer	0.000142	0.00252	CbGeAlD
Methotrexate—ABCB1—epithelium—pharynx cancer	0.000134	0.00237	CbGeAlD
Methotrexate—ABCB1—trachea—pharynx cancer	0.000118	0.0021	CbGeAlD
Methotrexate—ABCG2—lymph node—pharynx cancer	0.000118	0.00209	CbGeAlD
Methotrexate—ABCB1—lymphoid tissue—pharynx cancer	0.000103	0.00183	CbGeAlD
Methotrexate—ABCB1—spinal cord—pharynx cancer	9.33e-05	0.00165	CbGeAlD
Methotrexate—ABCB1—head—pharynx cancer	8.29e-05	0.00147	CbGeAlD
Methotrexate—ABCB1—lymph node—pharynx cancer	5.81e-05	0.00103	CbGeAlD
